Bonus Biogroup (TA:BONS) — Market Cap & Net Worth
Market Cap & Net Worth: Bonus Biogroup (BONS)
Bonus Biogroup (TA:BONS) has a market capitalization of $129.94 Million (ILA48.47 Billion) as of May 9, 2026. Listed on the TA stock exchange, this Israel-based company holds position #18205 globally and #234 in its home market, demonstrating a -1.19% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Bonus Biogroup's stock price ILA41.50 by its total outstanding shares 1167925311 (1.17 Billion). Analyse BONS operating cash flow to see how efficiently the company converts income to cash.
Bonus Biogroup Market Cap History: 2015 to 2026
Bonus Biogroup's market capitalization history from 2015 to 2026. Data shows change from $211.04 Million to $129.94 Million (-0.76% CAGR).
Bonus Biogroup Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Bonus Biogroup's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of BONS by Market Capitalization
Companies near Bonus Biogroup in the global market cap rankings as of May 9, 2026.
Key companies related to Bonus Biogroup by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $109.05 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #360 globally with a market cap of $74.28 Billion USD.
- UCB SA (BR:UCB): Ranked #510 globally with a market cap of $51.74 Billion USD ( €44.26 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #569 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $109.05 Billion | $429.82 |
| #360 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.28 Billion | $714.89 |
| #510 | UCB SA | BR:UCB | $51.74 Billion | €234.10 |
| #569 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Bonus Biogroup Historical Marketcap From 2015 to 2026
Between 2015 and today, Bonus Biogroup's market cap moved from $211.04 Million to $ 129.94 Million, with a yearly change of -0.76%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ILA129.94 Million | +67.34% |
| 2025 | ILA77.65 Million | +110.17% |
| 2024 | ILA36.95 Million | -29.76% |
| 2023 | ILA52.60 Million | -12.95% |
| 2022 | ILA60.43 Million | -84.68% |
| 2021 | ILA394.53 Million | +162.50% |
| 2020 | ILA150.30 Million | +8.60% |
| 2019 | ILA138.40 Million | +19.14% |
| 2018 | ILA116.17 Million | -32.55% |
| 2017 | ILA172.21 Million | -1.96% |
| 2016 | ILA175.66 Million | -16.77% |
| 2015 | ILA211.04 Million | -- |
End of Day Market Cap According to Different Sources
On May 9th, 2026 the market cap of Bonus Biogroup was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $129.94 Million USD |
| MoneyControl | $129.94 Million USD |
| MarketWatch | $129.94 Million USD |
| marketcap.company | $129.94 Million USD |
| Reuters | $129.94 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Bonus Biogroup
Bonus BioGroup Ltd., a clinical-stage biotechnology company, develops products based on tissue engineering and cell therapy. The company's products under development include BonoFill for the treatment of bone tissue regeneration in maxillofacial and orthopedic indications, and defects in limb and jaw bones which is in Phase II clinical trial, as well as in a preclinical stage for the treatment of… Read more